ARCHIMED Acquires Majority Stake in Cellese
April 9, 2024
Global healthcare private equity firm ARCHIMED has acquired a majority stake in Cellese, the Irvine, California–based developer of growth factor- and exosome-based dermo-cosmetic products sold under the AnteAGE brand. ARCHIMED will support Cellese's commercialization and international expansion while founder Ian Sanderson and his family roll a meaningful portion of proceeds into a minority stake.
- Buyers
- ARCHIMED
- Targets
- Cellese
- Industry
- Consumer Products
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics
September 25, 2025
Biotechnology
ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.
-
ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)
November 3, 2021
Biotechnology
Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.
-
ARCHIMED Acquires Majority Stake in Cardioline
November 17, 2021
Medical Devices
Trans-Atlantic private equity firm ARCHIMED has acquired a majority stake in Cardioline, a Trento, Italy-based maker of cardiology devices and Europe's largest provider of cardiology-focused telemedicine. The investment, made through ARCHIMED's MED III Fund, will support Cardioline's product and software development, international expansion and potential add-on M&A while founders retain a significant minority stake and remain in management.
-
ARCHIMED (via Duomodiag) Acquires DIESSE Diagnostica Senese SpA
May 13, 2019
Medical Devices
ARCHIMED, through its MED II-backed holding company Duomodiag Sarl, acquired Italian in vitro diagnostics specialist DIESSE Diagnostica Senese SpA in a cross-border carve-out completed on May 13, 2019. The deal — financed by MPS Capital Services and BPER — purchased DIESSE from its founders and Orphée SA (the Swiss subsidiary of the PZ Cormay group) to accelerate product innovation and expand market penetration internationally.
-
ARCHIMED Acquires Majority Stake in Xpress Biologics
October 5, 2021
Biotechnology
ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.
-
ARCHIMED Acquires Majority Stake in Arkstone Medical Solutions
August 6, 2025
Healthcare Services
ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Arkstone Medical Solutions, a provider of AI/ML-driven clinical decision support and antimicrobial stewardship tools. The investment will support Arkstone's product development, global expansion and R&D to accelerate adoption of its OneChoice Report in laboratories and healthcare providers worldwide.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.